Microvascular density of breast cancer in bone metastasis: Influence of therapy

Tamás Lörincz, J. Tóth, M. Szendrői, J. Tímár

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: Bone is the most frequent site of systemic progression of breast cancer (BRC). Angiosuppressive therapy has now entered the management of progressing cancers, therefore it is clinically important to obtain information on vascular endothelial growth factor (VEGF) expression and microvessel density (MVD) of bone metastasis of BRC. Materials and Methods: VEGF expression and MVD were evaluated in bone metastases of BRC immunohistochemically in paraffin samples of 18 patients and compared to their primary tumors. MVD was determined by using the hot-spot method and the endothelial marker, CD34. Results: Chemo- and/or endocrine therapy-naïve BRC cases progressed to the bone with a concomitant increase in their angiogenic potential, suggesting that this is the "natural history" of BRC progression. On the other hand, this study revealed that vascularization of the bone metastases of BRC patients that had received adjuvant (chemo- and/or endocrine) therapy was significantly decreased compared to the corresponding primary tumors, also supported by a decreased VEGF expression in metastases, both suggesting that the treatment significantly affected the angiogenic phenotype of the progressing disease. Conclusion: Angiosuppressive therapy is a new approach to cancer management including BRC and is frequently applied in the advanced stage of disease. Tumors with a prominent angiogenic phenotype (high MVD and VEGF) are primary candidates for such regimes. The fact that chemo-endocrine adjuvant therapy of BRC resulted in a weaker angiogenic phenotype in bone metastases compared to non-treated cases may suggest that these latter patients are better candidates for angiosuppressive interventions.

Original languageEnglish
Pages (from-to)3075-3082
Number of pages8
JournalAnticancer Research
Volume25
Issue number4
Publication statusPublished - Jul 2005

Fingerprint

Bone Neoplasms
Breast Neoplasms
Neoplasm Metastasis
Microvessels
Vascular Endothelial Growth Factor A
Bone and Bones
Therapeutics
Neoplasms
Phenotype
Natural History
Paraffin
Bone Density

Keywords

  • Bone metastasis
  • Breast cancer
  • Lung cancer
  • Microvessel density
  • Renal cell cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Microvascular density of breast cancer in bone metastasis : Influence of therapy. / Lörincz, Tamás; Tóth, J.; Szendrői, M.; Tímár, J.

In: Anticancer Research, Vol. 25, No. 4, 07.2005, p. 3075-3082.

Research output: Contribution to journalArticle

@article{8b84030728b7453a8d91101a1bb10c2b,
title = "Microvascular density of breast cancer in bone metastasis: Influence of therapy",
abstract = "Background: Bone is the most frequent site of systemic progression of breast cancer (BRC). Angiosuppressive therapy has now entered the management of progressing cancers, therefore it is clinically important to obtain information on vascular endothelial growth factor (VEGF) expression and microvessel density (MVD) of bone metastasis of BRC. Materials and Methods: VEGF expression and MVD were evaluated in bone metastases of BRC immunohistochemically in paraffin samples of 18 patients and compared to their primary tumors. MVD was determined by using the hot-spot method and the endothelial marker, CD34. Results: Chemo- and/or endocrine therapy-na{\"i}ve BRC cases progressed to the bone with a concomitant increase in their angiogenic potential, suggesting that this is the {"}natural history{"} of BRC progression. On the other hand, this study revealed that vascularization of the bone metastases of BRC patients that had received adjuvant (chemo- and/or endocrine) therapy was significantly decreased compared to the corresponding primary tumors, also supported by a decreased VEGF expression in metastases, both suggesting that the treatment significantly affected the angiogenic phenotype of the progressing disease. Conclusion: Angiosuppressive therapy is a new approach to cancer management including BRC and is frequently applied in the advanced stage of disease. Tumors with a prominent angiogenic phenotype (high MVD and VEGF) are primary candidates for such regimes. The fact that chemo-endocrine adjuvant therapy of BRC resulted in a weaker angiogenic phenotype in bone metastases compared to non-treated cases may suggest that these latter patients are better candidates for angiosuppressive interventions.",
keywords = "Bone metastasis, Breast cancer, Lung cancer, Microvessel density, Renal cell cancer",
author = "Tam{\'a}s L{\"o}rincz and J. T{\'o}th and M. Szendrői and J. T{\'i}m{\'a}r",
year = "2005",
month = "7",
language = "English",
volume = "25",
pages = "3075--3082",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "4",

}

TY - JOUR

T1 - Microvascular density of breast cancer in bone metastasis

T2 - Influence of therapy

AU - Lörincz, Tamás

AU - Tóth, J.

AU - Szendrői, M.

AU - Tímár, J.

PY - 2005/7

Y1 - 2005/7

N2 - Background: Bone is the most frequent site of systemic progression of breast cancer (BRC). Angiosuppressive therapy has now entered the management of progressing cancers, therefore it is clinically important to obtain information on vascular endothelial growth factor (VEGF) expression and microvessel density (MVD) of bone metastasis of BRC. Materials and Methods: VEGF expression and MVD were evaluated in bone metastases of BRC immunohistochemically in paraffin samples of 18 patients and compared to their primary tumors. MVD was determined by using the hot-spot method and the endothelial marker, CD34. Results: Chemo- and/or endocrine therapy-naïve BRC cases progressed to the bone with a concomitant increase in their angiogenic potential, suggesting that this is the "natural history" of BRC progression. On the other hand, this study revealed that vascularization of the bone metastases of BRC patients that had received adjuvant (chemo- and/or endocrine) therapy was significantly decreased compared to the corresponding primary tumors, also supported by a decreased VEGF expression in metastases, both suggesting that the treatment significantly affected the angiogenic phenotype of the progressing disease. Conclusion: Angiosuppressive therapy is a new approach to cancer management including BRC and is frequently applied in the advanced stage of disease. Tumors with a prominent angiogenic phenotype (high MVD and VEGF) are primary candidates for such regimes. The fact that chemo-endocrine adjuvant therapy of BRC resulted in a weaker angiogenic phenotype in bone metastases compared to non-treated cases may suggest that these latter patients are better candidates for angiosuppressive interventions.

AB - Background: Bone is the most frequent site of systemic progression of breast cancer (BRC). Angiosuppressive therapy has now entered the management of progressing cancers, therefore it is clinically important to obtain information on vascular endothelial growth factor (VEGF) expression and microvessel density (MVD) of bone metastasis of BRC. Materials and Methods: VEGF expression and MVD were evaluated in bone metastases of BRC immunohistochemically in paraffin samples of 18 patients and compared to their primary tumors. MVD was determined by using the hot-spot method and the endothelial marker, CD34. Results: Chemo- and/or endocrine therapy-naïve BRC cases progressed to the bone with a concomitant increase in their angiogenic potential, suggesting that this is the "natural history" of BRC progression. On the other hand, this study revealed that vascularization of the bone metastases of BRC patients that had received adjuvant (chemo- and/or endocrine) therapy was significantly decreased compared to the corresponding primary tumors, also supported by a decreased VEGF expression in metastases, both suggesting that the treatment significantly affected the angiogenic phenotype of the progressing disease. Conclusion: Angiosuppressive therapy is a new approach to cancer management including BRC and is frequently applied in the advanced stage of disease. Tumors with a prominent angiogenic phenotype (high MVD and VEGF) are primary candidates for such regimes. The fact that chemo-endocrine adjuvant therapy of BRC resulted in a weaker angiogenic phenotype in bone metastases compared to non-treated cases may suggest that these latter patients are better candidates for angiosuppressive interventions.

KW - Bone metastasis

KW - Breast cancer

KW - Lung cancer

KW - Microvessel density

KW - Renal cell cancer

UR - http://www.scopus.com/inward/record.url?scp=22944486013&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22944486013&partnerID=8YFLogxK

M3 - Article

C2 - 16080568

AN - SCOPUS:22944486013

VL - 25

SP - 3075

EP - 3082

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 4

ER -